☆ 4.4 Article

Prognostic modelling of number of patients with retinal vein occlusion in anti-VEGF therapy

ACTA OPHTHALMOLOGICA (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Ophthalmology

An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma

Faruque Ghanchi et al.

Summary: In real-world settings, suboptimal compliance with frequent treatments and assessments can lead to undertreatment of eye diseases and pose a risk to vision. Longer-acting therapies that reduce the burden of treatment interventions are needed. Several longer-acting interventions for various eye diseases have been developed or are in late-phase development. This review provides an overview of these interventions and discusses the potential use of artificial intelligence to tailor treatment efficacy and reduce treatment burden.

EYE (2022)

添加到收藏夹

Article Medicine, General & Internal

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

Jeffrey S. Heier et al.

Summary: The primary results of two Phase 3 trials show that faricimab can effectively improve visual acuity for patients with nAMD at intervals of up to 16 weeks, with comparable safety profile to aflibercept. This suggests that faricimab has the potential to reduce treatment burden by extending the time between injections while maintaining efficacy.

LANCET (2022)

添加到收藏夹

Article Ophthalmology

Long-term outcomes of anti-VEGF treatment of macular oedema due to retinal vein occlusions

Paolo Corazza et al.

Summary: This study aimed to compare the outcomes of ranibizumab and aflibercept in the treatment of retinal vein occlusion (RVO) over a maximum follow-up of five years. The results showed that there were no significant differences in visual benefits between the two treatments, except in the first year for ranibizumab-treated BRVO eyes. However, aflibercept-treated CRVO and BRVO eyes required significantly fewer injections during the follow-up period.

EUROPEAN JOURNAL OF OPHTHALMOLOGY (2022)

添加到收藏夹

Editorial Material Ophthalmology

Retinal vein occlusion (RVO) guideline: executive summary

Luke Nicholson et al.

EYE (2022)

添加到收藏夹

Article Ophthalmology

Intravitreal Injection of Brolucizumab for Recalcitrant Macular Edema due to Central Retinal Vein Occlusion: A Small Case Series

Debdulal Chakraborty et al.

Summary: This study is a case series that demonstrates significant improvement in visual acuity and reduction of macular edema in patients with recalcitrant ME secondary to CRVO after intravitreal injection of BRZ. Patients showed sustained improvement up to 12 weeks but experienced a recurrence of fluid at week 16, requiring a second injection.

CASE REPORTS IN OPHTHALMOLOGY (2022)

添加到收藏夹

Review Ophthalmology

Markedly decreasing incidence of cause-specific blindness in Saxony (Eastern Germany)

Heiner Claessen et al.

Summary: The age- and sex-standardized incidence of blindness decreased among all common causes of blindness in Saxony in the last decade, with a significant reduction observed in the adjusted incidence rates for various causes like age-related macular degeneration, glaucoma, diabetic retinopathy, myopia, optic atrophy, and cataract.

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2021)

添加到收藏夹

Article Ophthalmology

Modelling and prognostication of growth in the number of patients treated for neovascular age-related macular degeneration

Ivan Potapenko et al.

Summary: The study illustrates a rapid increase in the number of patients receiving anti-VEGF therapy in Denmark from 2007 to 2019, leading to significant pressure on the healthcare system. The growth was initially driven by patients receiving extended periods of treatment, but demographic changes became the main factor later on. Additionally, treatment incidences slightly increased, particularly for individuals over 85 years old.

ACTA OPHTHALMOLOGICA (2021)

添加到收藏夹

Article Public, Environmental & Occupational Health

Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study

Rupert R. A. Bourne et al.

Summary: The age-adjusted prevalence of blindness has decreased over the past three decades, but the number of people affected has actually increased due to population growth. By 2050, it is predicted that there will be an increase in the number of individuals suffering from vision impairments, highlighting the need for continued efforts in addressing this global issue.

LANCET GLOBAL HEALTH (2021)

添加到收藏夹

Article Ophthalmology

HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration

Pravin U. Dugel et al.

OPHTHALMOLOGY (2020)

添加到收藏夹

Article Ophthalmology

Neovascular Age-Related Macular Degeneration in the Very Old (>= 90 Years): Epidemiology, Adherence to Treatment, and Comparison of Efficacy

Yousif Subhi et al.

JOURNAL OF OPHTHALMOLOGY (2017)

添加到收藏夹

Article Ophthalmology

Anti-VEGF treatment in branch retinal vein occlusion: a real-world experience over 4 years

Sandra Rezar et al.

ACTA OPHTHALMOLOGICA (2015)

添加到收藏夹

Article Ophthalmology

Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion The 24-Week Results of the VIBRANT Study

Peter A. Campochiaro et al.

OPHTHALMOLOGY (2015)

添加到收藏夹

Article Ophthalmology

A 4-Year Longitudinal Study of 555 Patients Treated with Ranibizumab for Neovascular Age-related Macular Degeneration

Annette Rasmussen et al.

OPHTHALMOLOGY (2013)

添加到收藏夹

Article Ophthalmology

Time Trends in the Incidence and Causes of Blindness in Israel

Alon Skaat et al.

AMERICAN JOURNAL OF OPHTHALMOLOGY (2012)

添加到收藏夹

Article Ophthalmology

Incidence of Legal Blindness From Age-Related Macular Degeneration in Denmark: Year 2000 to 2010

Sara Brandi Bloch et al.

AMERICAN JOURNAL OF OPHTHALMOLOGY (2012)

添加到收藏夹

Article Ophthalmology

Ranibizumab for Macular Edema following Branch Retinal Vein Occlusion Six-Month Primary End Point Results of a Phase III Study

Peter A. Campochiaro et al.

OPHTHALMOLOGY (2010)

添加到收藏夹

Review Ophthalmology

Branch retinal vein occlusion: Pathogenesis, visual prognosis, and treatment modalities

Jiri Rehak et al.

CURRENT EYE RESEARCH (2008)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.